Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Author
Besser, R.
Shepherd, Maggie
McDonald, Timothy J.
Shields, Beverley
Knight, Bridget A.
Ellard, Sian
Hattersley, Andrew T.
Date
2011-02Journal
Diabetes careType
Clinical TrialResearch Support, Non-U.S. Gov't
Publisher
HighwireDOI
10.2337/dc10-1293Rights
Archived with thanks to Diabetes careMetadata
Show full item recordAbstract
Hepatocyte nuclear factor 1-α (HNF1A)/hepatocyte nuclear factor 4-α (HNF4A) maturity-onset diabetes of the young (MODY) is frequently misdiagnosed as type 1 diabetes, and patients are inappropriately treated with insulin. Blood C-peptide can aid in the diagnosis of MODY, but practical reasons limit its widespread use. Urinary C-peptide creatinine ratio (UCPCR), a stable measure of endogenous insulin secretion, is a noninvasive alternative. We aimed to compare stimulated UCPCR in adults with HNF1A/4A MODY, type 1 diabetes, and type 2 diabetes.